# Portico Next Generation Approval Study

Study · id `cardio:ct-nct04011722` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04011722](<https://clinicaltrials.gov/study/NCT04011722>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT04011722

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 333 participants.

## Technical summary

Registry record NCT04011722. Non-randomized; no masking; primary purpose treatment. Start 2019-09-17 (actual); primary completion 2023-01-12 (actual). Results posted on 2024-07-01.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 333 participants (enrolled count; ClinicalTrials.gov record NCT04011722, source copy `cardio:ctgov-nct04011722-2026-11-17`, retrieved 2026-11-18)
- Started: 2019-09-17 (actual) (ClinicalTrials.gov record NCT04011722, source copy `cardio:ctgov-nct04011722-2026-11-17`, retrieved 2026-11-18)
- Primary completion: 2023-01-12 (actual) (ClinicalTrials.gov record NCT04011722, source copy `cardio:ctgov-nct04011722-2026-11-17`, retrieved 2026-11-18)
- Completion: 2033-01 (anticipated) (ClinicalTrials.gov record NCT04011722, source copy `cardio:ctgov-nct04011722-2026-11-17`, retrieved 2026-11-18)
- Results first posted: 2024-07-01 (ClinicalTrials.gov record NCT04011722, source copy `cardio:ctgov-nct04011722-2026-11-17`, retrieved 2026-11-18)
- Countries: United States; Australia; Denmark; Italy; United Kingdom (ClinicalTrials.gov record NCT04011722, source copy `cardio:ctgov-nct04011722-2026-11-17`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04011722-2026-11-17`, retrieved 2026-11-18)

## The registry's words

- Brief title: Portico Next Generation Approval Study
- Condition: Symptomatic Severe Aortic Stenosis
- Intervention (Device): Portico™ NG (Navitor) Valve and FlexNav™ Delivery System
- Intervention (Device): Navitor Titan Valve (35mm) Valve and Large FlexNav™ Delivery System
- Lead sponsor: Abbott Medical Devices
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Aortic stenosis (`cardio:aortic-stenosis`)
- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry lists this organization as the lead sponsor: Abbott (`cardio:abbott`)

## Provenance

Content hash: a1ac592c48c8442009ebbfb3f11136ebb7fa3e9d5a59f3f0e87ddd38c63dd80c
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
